You never know, it might make sense for Lily or Lily and Boehringer Ingelheim to take out RVX together since they co-own Jardiance. We don't seem to talk too much about BI but remember that it is significantly bigger than Lily, privately owned and Christoph Boehringer, who owns over 1 million RVX shares, has likely made his cousin, the CEO of BI, aware of the goings on at RVX. 

As far as replacing Don goes, to me it's a little late if it's about to be sold. I had suggested about 5 years ago that RVX might be better served by a CEO with real biotech credentials but unless we are carrying on long term (I hope not) no point changing IMO.